Loading...
•
Sep 30, 2025
Sanara MedTech Q3 2025 Earnings Report
Reported a 22% increase in net revenue and achieved positive net income from continuing operations in Q3 2025.
Key Takeaways
Sanara MedTech posted strong Q3 2025 results, highlighted by significant revenue growth and improved profitability driven by soft tissue repair product sales.
Net revenue rose to $26.3 million, driven by growth in soft tissue repair product sales.
Net income from continuing operations reached $0.8 million, a reversal from the prior year's loss.
Adjusted EBITDA more than doubled to $4.9 million from $2.6 million in Q3 2024.
Gross margin improved to 93% due to higher-margin product mix.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Sanara expects to continue executing its commercial strategy while investing in its core surgical business for sustainable revenue growth and profitability.
Positive Outlook
- Focused strategy on core surgical business post-THP exit.
- Strengthening distribution network with independent reps.
- Continued penetration into new and existing healthcare facilities.
- Increased surgeon adoption driving sales.
- Operational efficiencies expected from strategic realignment.
Challenges Ahead
- Losses from discontinued THP operations impacted overall bottom line.
- Higher interest expense weighed on net income.
- Continued R&D and SG&A spending pressuring margins.
- Equity method investments generating losses.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...